Dyne Therapeutics (DYN)

• Market cap: $1.35B
• 1 day: -3.24%
• 5 days: -3.63%
• 1 month: -14.88%
• 3 months: -53.52%
• 6 months: -64.89%
• Year to date: -53.02%
• 1 year: -56.93%
• 5 years: -49.96%
• 10 years: -49.96%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Employees: 191

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

10% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 62

9% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 34

1% less funds holding

Funds holding: 201 [Q3] → 199 (-2) [Q4]

2.02% less ownership

Funds ownership: 111.67% [Q3] → 109.65% (-2.02%) [Q4]

30% less funds holding in top 10

Funds holding in top 10: 10 [Q3] → 7 (-3) [Q4]

35% less capital invested

Capital invested by funds: $4.02B [Q3] → $2.63B (-$1.39B) [Q4]

65% less call options, than puts

Call options by funds: $3.57M | Put options by funds: $10.3M

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $45 276% upside
• Avg. target: $48 300% upside
• High target: $50 318% upside

7 analyst ratings

• positive: 7 100%
• neutral: 0 0%
• negative: 0 0%

BMO Capital Kostas Biliouris 27% 1-year accuracy 6 / 22 met price target	318% upside $50	Outperform Initiated	12 Mar 2025
Scotiabank Louise Chen 37% 1-year accuracy 52 / 142 met price target	318% upside $50	Sector Outperform Initiated	7 Mar 2025
Chardan Capital Keay Nakae 14% 1-year accuracy 10 / 69 met price target	318% upside $50	Buy Maintained	28 Feb 2025
Piper Sandler Edward Tenthoff 21% 1-year accuracy 8 / 39 met price target	301% upside $48	Overweight Maintained	28 Feb 2025
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 112 / 352 met price target	285% upside $46	Buy Maintained	28 Feb 2025